LCM
VKTX icon

Legato Capital Management’s Viking Therapeutics VKTX Stock Holding History

Legato Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-7,200
Closed -$290K – 622
2024
Q4 		$290K Buy
7,200
+1,905
+36% +$109K 0.04% 502
2024
Q3 		$335K Buy
5,295
+755
+17% +$44.3K 0.04% 496
2024
Q2 		$241K Sell
4,540
-10,162
-69% -$666K 0.03% 507
2024
Q1 		$1.21M Sell
14,702
-18,153
-55% -$808K 0.15% 235
2023
Q4 		$611K Buy
+32,855
New +$430K 0.08% 375

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Legato Capital Management's VKTX Position: Q1 2025 in Review

Legato Capital Management sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 7,200 shares — an estimated $290K sold.

Legato Capital Management first reported a position in VKTX in Q4 2023 and held it in 5 quarters. The position peaked at $1.21M in Q1 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Legato Capital Management reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Legato Capital Management sold 7,200 Viking Therapeutics shares in Q1 2025, an estimated $290K.
  • Legato Capital Management first reported a position in Viking Therapeutics in Q4 2023 and held it in 5 quarters.
  • Legato Capital Management's Viking Therapeutics position peaked at $1.21M in Q1 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Legato Capital Management's 13F filing for Q1 2025, filed 6 May 2025.